Affordable Access

Access to the full text

Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231

  • Bayoumy, Sherif1
  • Verberk, Inge M. W.1
  • den Dulk, Ben1
  • Hussainali, Zulaiga1
  • Zwan, Marissa2
  • van der Flier, Wiesje M.2, 2
  • Ashton, Nicholas J.3, 4, 5, 6
  • Zetterberg, Henrik3, 7, 8, 9, 10
  • Blennow, Kaj3, 7
  • Vanbrabant, Jeroen11
  • Stoops, Erik11
  • Vanmechelen, Eugeen11
  • Dage, Jeffrey L.12, 13
  • Teunissen, Charlotte E.1
  • 1 Amsterdam UMC, Boelelaan 1117, Amsterdam, 1081 HV, The Netherlands , Amsterdam (Netherlands)
  • 2 Amsterdam UMC, Amsterdam, The Netherlands , Amsterdam (Netherlands)
  • 3 The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden , Mölndal (Sweden)
  • 4 University of Gothenburg, Gothenburg, Sweden , Gothenburg (Sweden)
  • 5 Maurice Wohl Institute Clinical Neuroscience Institute, London, UK , London (United Kingdom)
  • 6 NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK , London (United Kingdom)
  • 7 Sahlgrenska University Hospital, Mölndal, Sweden , Mölndal (Sweden)
  • 8 UCL Institute of Neurology, Queen Square, London, UK , London (United Kingdom)
  • 9 UK Dementia Research Institute at UCL, London, UK , London (United Kingdom)
  • 10 Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China , Hong Kong (China)
  • 11 ADx NeuroSciences NV, Technologiepark 94, Gent, Belgium , Gent (Belgium)
  • 12 Eli Lilly and Company, Indianapolis, IN, 46285, USA , Indianapolis (United States)
  • 13 Indiana University School of Medicine, Indianapolis, IN, 46202, USA , Indianapolis (United States)
Published Article
Alzheimer's Research & Therapy
BioMed Central
Publication Date
Dec 04, 2021
DOI: 10.1186/s13195-021-00939-9
Springer Nature
  • Research


IntroductionStudies using different assays and technologies showed highly promising diagnostic value of plasma phosphorylated (P-)tau levels for Alzheimer’s disease (AD). We aimed to compare six P-tau Simoa assays, including three P-tau181 (Eli Lilly, ADx, Quanterix), one P-tau217 (Eli Lilly), and two P-tau231 (ADx, Gothenburg).MethodsWe studied the analytical (sensitivity, precision, parallelism, dilution linearity, and recovery) and clinical (40 AD dementia patients, age 66±8years, 50%F; 40 age- and sex-matched controls) performance of the assays.ResultsAll assays showed robust analytical performance, and particularly P-tau217 Eli Lilly; P-tau231 Gothenburg and all P-tau181 assays showed robust clinical performance to differentiate AD from controls, with AUCs 0.936–0.995 (P-tau231 ADx: AUC = 0.719). Results obtained with all P-tau181 assays, P-tau217 Eli Lilly assay, and P-tau231 Gothenburg assay strongly correlated (Spearman’s rho > 0.86), while correlations with P-tau231 ADx results were moderate (rho < 0.65).DiscussionP-tau isoforms can be measured robustly by several novel high-sensitive Simoa assays.

Report this publication


Seen <100 times